 Geoffroy O, Tassart M, Le Blanche A, Khalil A, Duedal V, Rossert J, et
al. Upper extremity digital subtraction venography with gadoterate
meglumine before fistula creation for hemodialysis. Kidney Int 2001;
59:1491-7.
61. Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, et al. Prevention of contrast-induced nephropathy with
sodium bicarbonate. JAMA 2004;291:2328-31.
62. Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A, et al.
Acetylcysteine for prevention of acute deterioration of renal function
following elective coronary angiography and intervention. JAMA
2003;289:553-7.
63. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG,
et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.
J Am Soc Nephrol 2006;17:2359-62.
64. Schuman E, Standage BA, Ragsdale JW, Heinl P. Achieving vascular
access success in the quality outcomes era. Am J Surg 2004;187:585-9;
discussion 589.
65. Parmley MC, Broughan TA, Jennings WC. Vascular ultrasonography
prior to dialysis access surgery. Am J Surg 2002;184:568-72.
66. Asif A, Cherla G, Merrill D, Cipleu CD, Tawakol JB, Epstein DL, et al.
Venous mapping using venography and the risk of radiocontrastinduced nephropathy. Semin Dial 2005;18:239-42.
67. Paksoy Y, Gormus N, Tercan MA. Three-dimensional contrast-enhanced magnetic resonance angiography (3-D CE-MRA